Tolterodin

Tolterodin
(IUPAC) ime
	(R)-2-[3-(diizopropilamino)-1-fenilpropil]-4-metilfenol
Klinički podaci
Robne marke	Detrol
AHFS/Drugs.com	Monografija
MedlinePlus	a699026
Identifikatori
CAS broj	124937-51-5
ATC kod	G04BD07
PubChem	443879
DrugBank	APRD00146
ChemSpider	391967
UNII	WHE7A56U7K
KEGG	D00646
ChEBI	CHEBI:9622
ChEMBL	CHEMBL1382
Hemijski podaci
Formula	C22H31NO
Mol. masa	325,488 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1 ; Key: OOGJQPCLVADCPB-HXUWFJFHSA-N
Farmakokinetički podaci
Bioraspoloživost	77%
Vezivanje za proteine plazme	Aproksimativno 96,3%.
Poluvreme eliminacije	1,9-3,7 časa
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Tolterodine (Detrol, Detrusitol) je antimuskarinski lek, koji se koristi za tretiranje urinarne inkontinencije.^[6] Ovaj lek prodaje kompanija Pfizer u Kanadi i Sjedinjenim Državama pod brand imenom Detrol.

Upotreba

Prekomerna aktivnost detrusora (kontrakcije mišića mokraćne bešike) je najčešća forma urinarne inkontinencije starijih osoba. Ona je karakterisana neinhibiranim kontrakcijama bešike, što uzrokuje nekontrolisani nagon za pražnjenjem. Urinarna frekvencija, nagonska inkontinencija i noćna inkontinencija se javljaju. Abnormalne kontrakcije bešike koje se podudaraju sa potrebom pražnjenja se mogu meriti putem urodinamičkih studija. Tretman je treniranje bešike ili primena lekova koji inhibiraju kontrakcije bešike, kao što su oksibutinin i tolterodin.^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Philip Van Kerrebroeck, Karl Kreder, Udo Jonas, Norm Zinner, Alan Wein (2001). „Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder1”. Urology 57 (3): 414-421.
↑ Chapple CR. "Muscarinic receptor antagonists in the treatment of overactive bladder". Urology (55)5, Supp. 1:33-46, 2000.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Philip Van Kerrebroeck, Karl Kreder, Udo Jonas, Norm Zinner, Alan Wein (2001). „Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder1”. Urology 57 (3): 414-421.

[7] Chapple CR. "Muscarinic receptor antagonists in the treatment of overactive bladder". Urology (55)5, Supp. 1:33-46, 2000.

[1]